TAG
GSK
Hibsago approved as first antisense hep B therapy
Rajiv -
GSK's Hibsago (bepirovirsen) is the first antisense therapy FDA-approved for chronic hepatitis B, with a 19% functional cure rate in Phase 3 trials.


